Evidence map›Paper›PMID 42165084›Full record

ArticleJHLT open2026

Glucagon-like peptide-1 receptor agonists for weight loss in end-stage heart failure patients considered for heart transplantation.

Sambavan Jeyakumar, Ragavi Jeyakumar, Hunter Eckford, Desiree Robson, Liarna Honeysett, Lisa Raven, Ricardo Deveza, Andrew Jabbour, Eugene Kotlyar, Anne Keogh and 4 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in JHLT open, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors.

Sambavan JeyakumarUniversity of New South Wales, Sydney, Australia.
Ragavi JeyakumarUniversity of New South Wales, Sydney, Australia.
Hunter EckfordSt. Vincent's Hospital, Sydney, Australia.
Desiree RobsonSt. Vincent's Hospital, Sydney, Australia.
Liarna HoneysettSt. Vincent's Hospital, Sydney, Australia.
Lisa RavenUniversity of New South Wales, Sydney, Australia.
Ricardo DevezaSt. Vincent's Hospital, Sydney, Australia.
Andrew JabbourUniversity of New South Wales, Sydney, Australia.
Eugene KotlyarUniversity of New South Wales, Sydney, Australia.
Anne KeoghUniversity of New South Wales, Sydney, Australia.
Jerry R GreenfieldUniversity of New South Wales, Sydney, Australia.
Peter MacdonaldUniversity of New South Wales, Sydney, Australia.
Christopher HaywardUniversity of New South Wales, Sydney, Australia.
Kavitha MuthiahUniversity of New South Wales, Sydney, Australia.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Severe obesity is a relative exclusion criterion for heart transplantation. This study assessed glucagon-like peptide-1 receptor agonists (GLP-1 RAs) for weight loss as a bridge to heart transplantation candidacy. A retrospective study of end-stage heart failure (ESHF) outpatients commenced on semaglutide compared demographic, metabolic, and transplant listing data pre- and post-treatment. Nine patients (median pre-GLP-1 RA body mass index [BMI]: 35.9 kg/m

Indexed as

GLP-1 receptor agonistsHeart transplantationPre-transplant optimizationTransplant candidacyWeight loss

Identifiers

PMID42165084
PMCPMC13186067

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.